Drug Therapy
|3 min read
Implantable ‘Living Pharmacy’ Produces Multiple Drugs Inside the Body
New system generates oxygen, sustaining drug-producing cells for weeks
Updated |3 min read
Selective PARP Inhibitor Improves Survival in Breast Cancer Trial
|2 min read
New Drug Slows Rare, Debilitating Genetic Disease in Trials
The NIH-supported clinical trial could lead to the first effective treatment for ACDC disease
Updated |2 min read
PARP Inhibitor Delays Uterine Cancer Recurrence in Phase 2 Trial
There are currently no approved maintenance therapies for metastatic and recurrent uterine/endometrial cancer
|2 min read
mAb Combo Therapy Safe to Treat Advanced Cancers
CS1002 plus CS1003 showed promising antitumor activity and had a manageable safety profile across a broad dosing range in trials
|2 min read
Arginine Starvation Abates Rare Lung Cancer
The treatment significantly increases the survival of people with malignant mesothelioma, according to results from Phase 3 trial
|2 min read
mAb–Drug Therapy Combo Improves NSC Lung Cancer
Phase 2 trial finds durvalumab–ceralasertib boosted immune response and improved outcomes in patients with lung cancer
|1 min read
Androgen Receptor Modulator Drug Could Improve Breast Cancer
Phase 2 trial results indicate benefits of the new way of treating advanced ER+ breast cancer
|2 min read
Combination Hormone Therapy May Delay Cancer Progression
Prostate cancer affects 1 in 8 men and causes 34,000 deaths each year in the US
|3 min read
Comprehensive Analysis Reveals 370 Novel Anticancer Drug Targets
Second generation of the Cancer Dependency Map uncovers priority drug targets with strong links to specific cancer types
|2 min read
Genetic Priority Score Finetunes Drug Development
Innovative approach integrates genetic data to identify drug targets with high potential for clinical trial success
|2 min read
Bendamustine Treatment before CAR T-Cell Therapy May Be Detrimental
CAR T-cell therapy recipients with refractory lymphoma showed poorer treatment outcomes when treated with bendamustine
|3 min read
New Test Drug–Empagliflozin Combo Abates CKD Side Effects
Some 70 percent of patients who received the test drug with a standard-care drug experienced a significant drop in albuminuria
|2 min read
